Is multiple session of intralesional bleomycin mandatory for complete resolution of macrocystic lymphatic malformation?

ABSTRACT

Background: Intralesional bleomycin scelro-therapy has become a favored line of treatment for macrocystic lymphatic malformations. However the need for multiple sessions is a drawback associated with this treatment modality. Our aim is to document whether multiple session of intra-lesional sclero-therapy is necessary for complete resolution of cystic lymphatic malformation. Method: Intralesional bleomycin under Ultrasound guidance was used for macrocystic lymphangioma at concentration of 3mg/ml but not exceeding the total dose (1mg/kg) body weight for single session or cumulative dose of 5mg/kg. In all cases intralesional sclerosant (ILS) was installed under proper aseptic precaution in operation theatre in general anesthesia or sedation depending on the site or size of lesion and age of the patient. Age of patients at the time of enrolment in study ranged from 3 months to 18 years. Clinical examination was the main stay of diagnosis which was supplemented by USG and/or computed tomography. Compression of the lesion site was done for few hours wherever it was possible after the ILS session. Result: A total of 21 patients included in our study. The age ranged from 3 months to 18 years. Male to female ratio was 8:13. The most common site of involvement was neck and axilla followed by anterior chest wall and nape of the neck. Complete resolution after single session was observed in 90.5% cases where as surgery was required in 9.5% case. Major complication was observed in one patient, who had intralesional bleeding which was managed conservatively. Transient pain and fever was observed in 23.8% of cases. Only two patient required surgical intervention where one had persistent subcutaneous fibrotic nodule and other one did not respond to ILS. Conclusion: Intralesional bleomycin is an effective treatment for macrocystic lesion, and complete resolution may be achieved by single session of ILS if proper principle are followed.

KEY WORDS

Cystic hygroma - intralesional bleomycin - sclerosant

• REFERENCES

• 1 Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A. et al. Vascular anomalies classification: Recommendations from the international society for the study of vascular anomalies. Pediatrics 2015; 136: e203-14
• 2 Acevedo JL, Shah RK, Brietzke SE. Nonsurgical therapies for lymphangiomas: A systematic review. Otolaryngol Head Neck Surg 2008; 138: 418-24
• 3 Sharif M, Elsiddig IE, Atwan F. Complete resolution of cystic hygroma with single session of intralesional bleomycin. J Neonatal Surg 2012; 1: 44
• 4 Olímpio HdeO, Bustorff-Silva J, Oliveira Filho AG, Araujo KC. Cross-sectional study comparing different therapeutic modalities for cystic lymphangiomas in children. Clinics (Sao Paulo) 2014; 69: 505-8
• 5 Lee BB, Laredo J, Lee TS, Huh S, Neville R. Terminology and classification of congenital vascular malformations. Phlebology 2007; 22: 249-52
• 6 Mirza B, Ijaz L, Saleem M, Sharif M, Sheikh A. Cystic hygroma: An overview. J Cutan Aesthet Surg 2010; 3: 139-447
• 7 Mathur NN, Rana I, Bothra R, Dhawan R, Kathuria G, Pradhan T. et al. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol 2005; 69: 75-80
• 8 Dhrif AS, El Euch D, Daghfous M, Cherif F, Mokni M, Dhahri AB. Macrocystic lymphatic lymphangioma (cystic lymphangioma) of upper extremity: A case report. Arch Pediatr 2008; 15: 1416-9
• 9 Rattan KN, Kajal P, Kadian YS, Gupta R. Haemorrhage in a scrotal lymphangioma in a child: A rarity. Afr J Paediatr Surg 2009; 6: 110-1
• 10 Ameh EA, Nmadu PT. Cervical cystic hygroma: Pre-, intra-, and post-operative morbidity and mortality in Zaria, Nigeria. Pediatr Surg Int 2001; 17: 342-3
• 11 Niramis R, Watanatittan S, Rattanasuwan T. Treatment of cystic hygroma by intralesional bleomycin injection: Experience in 70 patients. Eur J Pediatr Surg 2010; 20: 178-82
• 12 Horbach SE, Rigter IM, Smitt JH, Reekers JA, Spuls PI, van der Horst CM. et al. Intralesional bleomycin injections for vascular malformations: A Systematic review and meta-analysis. Plast Reconstr Surg 2016; 137: 244-56
• 13 Zhang W, Chen G, Ren JG, Zhao YF. Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: A possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol 2013; 170: 1210-20
• 14 Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T. et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010; 43: 161-72
• 15 Xu DP, Zhai QK, Cheng C, Gong H, Wang HW, Wang XK. et al. Appraisal of efficacy and safety of intralesional injection of high concentration of bleomycin A5 for treatment of huge macrocystic lymphatic malformations in cervical region. J Craniofac Surg 2014; 25: 1707-9
• 16 Jain V, Mohta A, Sengar M, Bansal K, Valvi K. Use of intralesional bleomycin as primary therapy in macrocystic lymphangiomas. Indian J Dermatol Venereol Leprol 2013; 79: 524-5
• 17 Shankar VN, Ashwini NS, Praveena V. Lymphvasculogenesis and lymphangioma – An update. J Cancer Sci Ther 2011; 3: 5